Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.

ABSTRACT:

Importance

Immune checkpoint inhibitors (ICIs) have broadened the metastatic urothelial carcinoma (mUC) therapeutic scenario. The association of programmed death ligand 1 (PD-L1) with response and survival in patients treated with ICIs is still controversial.

Objectives

To evaluate the association of PD-L1 with response rate and overall survival among patients with mUC treated with ICIs.

Data sources

PubMed, Embase, American Society of Clinical Oncology and European Society for Medical Oncology Meeting Libraries, and Web of Science were searched up to December 10, 2023.

Study selection

Two authors independently screened the studies. Included studies were randomized and nonrandomized clinical trials enrolling patients with mUC receiving ICIs with available overa

SUBMITTER: Maiorano BA 

PROVIDER: S-EPMC10918499 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature